APPENDICES. A systematic review and economic model of the ...

More documents

Recommendations

Info

216 Appendix 12 Study Intervention Participants Outcomes Core symptoms Teacher (English and maths) rating of ADHD Parent rating of ADHD Reference Barkley et al., 2000 40 Co-existent problems Teacher rating of ODD Parent rating of ODD Self-rating of ODD Inclusion criteria 1. Diagnosis of ADHD 2. No history of motor or vocal tics or Tourette’s Syndrome 3. No history of cardiac surgery, high blood-pressure or cerebral vascular accident 4. No history of adverse reactions to stimulant medications 5. No history of hyperthyroidism 6. No pregnancy or lactation Arm 1 MPH 5-mg MPH capsule twice daily, morning and noon, for 1 week (Administered by parent and teacher) Source Updated search Setting USA Educational performance Not reported Psychological function Conners’ Continuous Performance Test (CPT) Stroop Word–Colour Association Test Diagnostic criteria DSM-IV Number Total randomised = 38 (male = 30/35) Total withdrawals = 3 Arm 2 MPH 10-mg MPH capsule twice daily, morning and noon, for 1 week (Administered by parent and teacher) Design Crossover trial Duration Treatment: 5 weeks (1 week per treatment arm) Depression or anxiety Not reported Reasons for withdrawals: Family problems: n = 2 Low IQ: n = 1 (57) Quality of life Not reported Adverse events Side effects: number and severity (teacher, parent, self) Arm 3 Adderall 5-mg capsule twice daily, morning and noon, for 1 week (Administered by parent and teacher) Randomisation procedure: Lower dose of each active medication always preceded the higher dose Age 14 years (mean), 12–17 years (range) Purpose To compare the treatment effectiveness of MPH and Adderall using systematic assessments of stimulant medication response in teenagers with ADHD as it may occur in routine outpatient clinical practice Additional outcomes Not reported IQ 103.9 (mean) Arm 4 Adderall 10-mg capsule twice daily, morning and noon, for 1 week (Administered by parent and teacher) Co-morbid disorders Not reported Diagnostic subtypes Not reported Additional information No relevant information reported
Core symptoms Educational performance Quality of life Adverse events Not reported Not reported Number of side-effects: parent rating [complete data for n = 31/35 (89%)] Placebo 5.1 (3.7) MPH 5 mg 5.4 (4.8) MPH 10 mg 5.5 (3.6) Adderall 5 mg 4.8 (3.4) Adderall 10 mg 5.1 (3.8) F = 0.23, p = NS Number of side-effects: English teacher rating [complete data for n = 13/35 (37%)] Placebo 3.8 (4.4) MPH 5 mg 3.2 (3.2) MPH 10 mg 3.6 (4.2) Adderall 5 mg 2.9 (2.6) Adderall 10 mg 3.1 (3.9) F = 0.59, p = NS Number of side-effects: maths teacher rating [complete data n = 15/35 (43%)] Placebo 3.2 (2.4) MPH 5 mg 1.9 (2.6) MPH 10 mg 3.1 (2.5) Adderall 5 mg 3.1 (2.4) Adderall 10 mg 3.9 (3.0) F = 1.73, p = NS Number of side-effects: self-rating Placebo 4.6 (3.6) MPH 5 mg 4.3 (4.1) MPH 10 mg 4.8 (4.1) Adderall 5 mg 4.7 (3.8) Adderall 10 mg 4.7 (3.3) F = 0.17, p = NS ADHD total parent rating: [complete data for n = 31/35 (89%)] Placebo 21.9 (12.5) MPH 5 mg 21.01 (11.4) MPH 10 mg 16.8 (9.7) Adderall 5 mg 21.3 (8.7) Adderall 10 mg 19.0 (9.2) F = 2.05, p = NS ADHD total English teacher rating: [complete data for n = 13/35 (37%)] Placebo 22.5 (14.0) MPH 5 mg 17.9 (14.8) MPH 10 mg 21.5 (14.1) Adderall 5 mg 21.9 (13.1) Adderall 10 mg 18.1 (11.6) F = 1.02, p = NS © Queen’s Printer and Controller of HMSO 2006. All rights reserved. ADHD total Maths teacher rating [complete data n = 15/35 (43%)] Placebo 17.7 (13.8) MPH 5 mg 12.2 (13.7) MPH 10 mg 14.0 (12.3) Adderall 5 mg 17.5 (14.2) Adderall 10 mg 16.4 (15.2) F = 1.78, p = NS Health Technology Assessment 2006; Vol. 10: No. 23 continued 217
Page 1 and 2:
Appendices A systematic review and
Page 3 and 4:
Clinical effectiveness information
Page 5 and 6:
Searches for systematic reviews in
Page 7 and 8:
19. methyl phenidate.mp. 20. methyl
Page 9 and 10:
43. attention deficit$.mp. 44. 42 o
Page 11 and 12:
MEDLINE in-process and other non-in
Page 13 and 14:
PsycINFO (1967-July 2004) Searched:
Page 15 and 16:
next aminopropane) or dynaphenyl or
Page 17 and 18:
or ritaline or riphenidate or rital
Page 19:
System for Information on Grey Lite
Page 22 and 23: 166 Appendix 2 S hyperkinetic S imp
Page 24 and 25: 168 Appendix 2 19. (eq5d or eq 5d o
Page 26 and 27: 170 Appendix 2 14. (person trade of
Page 28 and 29: 172 Appendix 3 Reference Reason for
Page 31: Appendix 4 © Queen’s Printer and
Page 34 and 35: 178 Appendix 5 8. Was the statistic
Page 36 and 37: 180 Appendix 6 Cost-effectiveness R
Page 38 and 39: 182 Appendix 7 Appropriateness of m
Page 40 and 41: 184 Appendix 7 Sensitivity analysis
Page 42 and 43: 186 Appendix 7 Sensitivity analysis
Page 44 and 45: 188 Appendix 8 Probability cost-eff
Page 47 and 48: Appendix 10 © Queen’s Printer an
Page 49 and 50: Health state Responder to ATX, no s
Page 51 and 52: Health state Responder to IR-MPH, R
Page 53 and 54: Health state Responder to ER-MPH, R
Page 55: #Baseline shift random effects mode
Page 58 and 59: 202 Appendix 12 Study Intervention
Page 62 and 63: 206 Appendix 12 Core symptoms Educa
Page 122 and 123:
266 Appendix 12 Core symptoms Educa
Page 124 and 125:
268 Appendix 12 Study Intervention
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
366 Appendix 13 Study characteristi
show all

APPENDICES. A systematic review and economic model of the ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?